Cargando...

HER2 status and disparities in luminal breast cancers

National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic diffe...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Med
Main Authors: Holowatyj, Andreana N., Ruterbusch, Julie J., Ratnam, Manohar, Gorski, David H., Cote, Michele L.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2016
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893351/
https://ncbi.nlm.nih.gov/pubmed/27250116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.757
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!